Buy the dip on AMAG, says Summer Street

|About: AMAG Pharmaceuticals, Inc. (AMAG)|By:, SA News Editor

Remember, says analyst Carol Werther, AMAG has  $214M in cash and revenues of $80M in 2013. At $22 per share, enterprise value is $261M, or just over 3x revenue. The company was also cash flow positive the last two quarters. Her team would be aggressive buyers at $17.

The stock is now off 7.4% to $20.24.

Previous: AMAG gets a CRL from the FDA on Feraheme